BioTech Mag Search: Biotech
Ex-Biogen chief and Editas chair Mullen becomes CRISPR biotech's new CEO amid C-suite shake-up
22 days ago - By Fierce Biotech
Ex-Biogen chief and Editas chair Mullen becomes CRISPR biotech's new CEO amid C-suite shake-up badams
Mon, 02/08/2021 - 08:40
Read more ...
The headlines of BioTech Mag
2nd International Conference on Generic Drugs and Biosimilars
2nd International Conference on Generic Drugs and Biosimilars
2nd International Conference on Generic Drugs and Biosimilars
2nd International Conference on Generic Drugs and Biosimilars
Diabetes induces dysregulation of microRNAs associated with survival...
Abstract Aims/hypothesis Diabetes mellitus causes a progressive loss of functional efficacy in stem cells, including cardiac progenitor cells. The underlying molecular...
Yoh, a Day & Zimmermann Company: Sr. Scientist Assay Development/CMC
Yoh, a Day & Zimmermann Company: Yoh has an exciting opportunity for an experienced Senior Scientist with expertise in CMC and Assay Development to join our Client's team in...
Putting blood pressure on the map-literally
New study shows the importance of considering local temperature and geography when measuring cardiovascular health....
Team receives $7.5 million in grants for studies on cocaine, oxycodone addiction
New large-scale studies could help us understand why some people are more prone to addiction....
Wriggling tadpoles may hold clue to how autism develops
The Cline Laboratory investigates how the brain responds to visual experience....
Miltenyi Biotec: Technical Training Specialist - Life Sciences
Miltenyi Biotec: At Miltenyi Biotec, 3,000 employees worldwide develop pioneering solutions for biomedical science and the clinical application of cell therapies. O... San...
A comparative study on the unified model based multifactor dimensionality...
For gene-gene interaction analysis, the multifactor dimensionality reduction method has been widely employed to reduce multi-levels of gene-gene interactions into high- or...
Critical Care Canada Forum 2020 Abstracts
A spotlight schizophrenia drug in Neurocrine's $2B Takeda deal flunks its...
When Takeda spun out a pipeline of experimental psychiatry drugs to Neurocrine in a $2 billion deal amid a post-merger shakeout, R&D chief Andy Plump described the therapies as...
Coronavirus-Like Particles Could Ensure Reliability of Simpler, Faster...